Genta Incorporated announced that the European Patent Office intends to grant two key patents related to the company’s intellectual property position on Genasense® (oblimersen sodium) Injection. These two patents will provide protection for compositions, sequences, and pharmaceutical uses of Genasense and related compounds that attack Bcl-2, the molecular target of Genasense action.

BioSolar, Inc. (BSRC.OB) is pleased to announce that earlier this week it filed a patent application to protect the unique inventions and processes behind its proprietary bio-based backsheet. The extensive patent application is expected to provide BioSolar full protection of its new BioBacksheet™ technology.